CJC-1295 side effects: what the literature reports

The short version: the published trials were short and in healthy adults, so the side-effect picture is incomplete. Here is what the literature describes.

TL;DR

• The most common side effects are injection-site reactions, flushing, headache, and mild water retention.
• Sustained growth hormone elevation can affect blood sugar.
• Long-term safety data are limited; the published trials were short and in healthy adults.

What it is

CJC-1295 is a modified version of growth hormone-releasing hormone (in plain English: a small protein that signals the pituitary to release growth hormone). Two forms exist: with DAC (a chemical anchor that extends half-life to about a week) and without DAC (also called modified GRF 1-29, which is short-acting). The side effect picture differs slightly between the two, mostly because of how long the signal stays active.

How side effects happen

Think of GHRH receptors as a doorbell. Sermorelin and short-acting CJC-1295 ring the doorbell once. CJC-1295 with DAC keeps the doorbell pressed for days. A longer signal raises the chance of growth hormone over-correction — which is why most reported side effects relate to fluid balance, blood sugar, and joint comfort.

What the research says

A 2006 trial in healthy adults reported no serious adverse reactions and found CJC-1295 relatively well tolerated (Teichman et al., J Clin Endocrinol Metab, 2006). Headache, flushing, and injection-site reactions are commonly reported. A follow-up study focused on growth hormone pulses rather than side effects (Ionescu & Frohman, J Clin Endocrinol Metab, 2006). These are short trials in healthy adults — long-term safety data is limited.

What to know

Effects described with growth hormone-axis stimulation include persistent joint pain, carpal-tunnel-style hand tingling, swelling in the feet that does not resolve overnight, blurred vision, and new high blood sugar readings. Anyone who has one of these should see a healthcare provider. CJC-1295 has no FDA approval, and its long-term safety in people has not been established.

The Halftime POV

The honest summary is that CJC-1295's safety record is short. Brief 2006 studies in healthy adults are not long-term safety data, and the longer signal of the DAC form raises questions those studies could not answer.

Related reading:

• CJC-1295: what this modified GHRH peptide is
• How CJC-1295 extends GHRH signaling: the mechanism
• CJC-1295 with DAC vs without DAC: how the two forms differ

FAQ

Q: What are the most common CJC-1295 side effects? A: Published trials report injection-site reactions (redness, mild swelling), flushing, headache, and water retention as the most common effects.

Q: Does CJC-1295 cause insulin resistance? A: Sustained activation of the growth hormone axis can mildly elevate blood sugar in some people. The short published trials of CJC-1295 do not settle its long-term effect on blood sugar.

Q: Is CJC-1295 FDA-approved? A: No. CJC-1295 is not FDA-approved as a finished drug product. Compounded CJC-1295 is not FDA-approved. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved.

Sources

• Teichman SL et al. — J Clin Endocrinol Metab, 2006: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295
• Ionescu M, Frohman LA — J Clin Endocrinol Metab, 2006: Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.